Matteucci Emanuela, Maroni Paola, Disanza Andrea, Bendinelli Paola, Desiderio Maria Alfonsina
Dipartimento di Scienze Biomediche per la Salute, Molecular Pathology Laboratory, Università degli Studi di Milano, Italy.
Istituto Ortopedico Galeazzi, IRCCS, Milano, Italy.
Biochim Biophys Acta. 2016 Jan;1863(1):64-76. doi: 10.1016/j.bbamcr.2015.10.010. Epub 2015 Oct 19.
The pathogenesis of bone metastasis is unclear, and much focus in metastatic biology and therapy relays on epigenetic alterations. Since DNA-methyltransferase blockade with 5-aza-2'-deoxycytidine (dAza) counteracts tumour growth, here we utilized dAza to clarify whether molecular events undergoing epigenetic control were critical for bone metastatization. In particular, we investigated the patterns of secreted-protein acidic and rich in cysteine (SPARC) and of Endothelin 1, affected by DNA methyltransferases in tumours, with the hypothesis that in bone metastasis a coordinate function of SPARC and Endothelin 1, if any occurs, was orchestrated by DNA methylation. To this purpose, we prepared a xenograft model with the clone 1833, derived from human-MDA-MB231 cells, and dAza administration slowed-down metastasis outgrowth. This seemed consequent to the reductions of SPARC and Endothelin 1 at invasive front and in the bone marrow, mostly due to loss of Twist. In the metastasis bulk Snail, partly reduced by dAza, might sustain Endothelin 1-SPARC cooperativity. Both SPARC and Endothelin 1 underwent post-translational control by miRNAs, a molecular mechanism that might explain the in vivo data. Ectopic miR29a reduced SPARC expression also under long-term dAza exposure, while Endothelin 1 down-regulation occurred in the presence of endogenous-miR98 expression. Notably, dAza effects differed depending on in vivo and in vitro conditions. In 1833 cells exposed to 30-days dAza, SPARC-protein level was practically unaffected, while Endothelin 1 induction depended on the 3'-UTR functionality. The blockade of methyltransferases leading to SPARC reduction in vivo, might represent a promising strategy to hamper early steps of the metastatic process affecting the osteogenic niche.
骨转移的发病机制尚不清楚,转移生物学和治疗的许多重点都集中在表观遗传改变上。由于用5-氮杂-2'-脱氧胞苷(dAza)阻断DNA甲基转移酶可对抗肿瘤生长,因此我们利用dAza来阐明经历表观遗传控制的分子事件对骨转移是否至关重要。特别是,我们研究了肿瘤中受DNA甲基转移酶影响的富含半胱氨酸的酸性分泌蛋白(SPARC)和内皮素1的模式,假设在骨转移中,SPARC和内皮素1的协同功能(如果存在)是由DNA甲基化精心安排的。为此,我们用源自人-MDA-MB231细胞的1833克隆制备了异种移植模型,dAza给药减缓了转移灶的生长。这似乎是由于侵袭前沿和骨髓中SPARC和内皮素1的减少,主要是由于Twist的缺失。在转移灶中,Snail部分被dAza降低,可能维持内皮素1-SPARC的协同作用。SPARC和内皮素1都受到miRNA的翻译后调控,这一分子机制可能解释体内数据。异位miR29a在长期dAza暴露下也降低了SPARC的表达,而在内源性miR98表达存在的情况下,内皮素1下调。值得注意的是,dAza的作用因体内和体外条件而异。在暴露于30天dAza的1833细胞中,SPARC蛋白水平实际上未受影响,而内皮素1的诱导取决于3'-UTR的功能。导致体内SPARC减少的甲基转移酶阻断可能是一种有前途的策略,可阻碍影响成骨微环境的转移过程的早期步骤。